February 12, 2025

Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 (under IFRS)

Company name: Solasia Pharma K.K.
Listing: Tokyo Stock Exchange
Securities code: 4597
URL: https://www.solasia.co.jp/en/
Representative: Yoshihiro Arai, President and Chief Executive Officer
Contact: Toshio Miyashita, Chief Financial Officer
TEL: +81-3-5843-8046

Scheduled date of ordinary general meeting of shareholders: March 26, 2025
Scheduled date to commence dividend payments: –
Scheduled date to file annual securities report: March 26, 2025
Preparation of supplementary material on financial results: Yes
Holding of financial results presentation meeting: Yes (for institutional investors and analysts)

(Millions of yen with fractional amounts discarded, unless otherwise noted)

1. Consolidated financial results for the fiscal year ended December 31, 2024 (from January 1, 2024 to December 31, 2024)

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
December 31, 2024	316	(48.7)	(1,951)	–	(1,961)	–	(1,941)	–
December 31, 2023	617	(43.5)	(1,139)	–	(1,135)	–	(1,112)	–

	Profit attributable to owners of parent		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Fiscal year ended	Millions of yen	%	Millions of yen	%	Yen	Yen
December 31, 2024	(1,941)	–	(1,933)	–	(9.77)	(9.77)
December 31, 2023	(1,112)	–	(1,103)	–	(6.62)	(6.62)

	Ratio of profit to equity attributable to owners of parent	Ratio of profit before tax to total assets	Ratio of operating profit to revenue
Fiscal year ended	%	%	%
December 31, 2024	(128.1)	(109.2)	(615.7)
December 31, 2023	(49.0)	(42.3)	(184.6)

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets	Equity attributable to owners of parent per share
As of	Millions of yen	Millions of yen	Millions of yen	%	Yen
December 31, 2024	1,362	1,156	1,156	84.9	5.30
December 31, 2023	2,229	1,875	1,875	84.1	10.78

(3) Consolidated cash flows

	Net cash provided by (used in) operating activities	Net cash provided by (used in) investing activities	Net cash provided by (used in) financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
December 31, 2024	(1,033)	(0)	1,180	886
December 31, 2023	(359)	(0)	275	728

2. Cash dividends

	Annual cash dividends per share					Total cash dividends (Annual)	Dividend payout ratio (Consolidated)	Ratio of dividends to equity attributable to owners of parent (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended December 31, 2023	–	0.00	–	0.00	0.00	–	–	–
Fiscal year ended December 31, 2024	–	0.00	–	0.00	0.00	–	–	–
Fiscal year ending December 31, 2025 (Forecast)	–	0.00	–	0.00	0.00		–	

3. Consolidated earnings forecasts for the fiscal year ending December 31, 2024 (from January 1, 2024 to December 31, 2024)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending December 31,2025	1,300	310.2	(650)	–	(650)	–	(650)	–	(650)	–	(2.98)

* Notes

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in scope of consolidation): None

(2) Changes in accounting policies and changes in accounting estimates

1) Changes in accounting policies required by IFRS: None
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None

(3) Number of issued shares (ordinary shares)

1) Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2024	218,458,910 shares
As of December 31, 2023	174,373,910 shares

2) Number of treasury shares at the end of the period

As of December 31, 2024	409,110 shares
As of December 31, 2023	430,910 shares

3) Average number of shares during the period

Fiscal year ended December 31, 2024	198,704,239 shares
Fiscal year ended December 31, 2023	168,131,901 shares

(**Reference) Summary of Non-consolidated Results**

1. Non-Consolidated financial results for the fiscal year ended December 31, 2024 (from January 1, 2024 to December 31, 2024)

(1) Non-Consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating income		Ordinary income		Net income	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
December 31, 2024	316	(48.7)	(840)	–	(869)	–	(868)	–
December 31, 2023	617	(43.5)	(688)	–	(678)	–	(679)	–

	Net income per share	Diluted net income per share
Fiscal year ended	Yen	Yen
December 31, 2024	(4.37)	(4.37)
December 31, 2023	(4.04)	(4.04)

(2) Non-Consolidated Financial Position

	Total assets	Net assets	Shareholders' equity ratio	Net assets per share
Fiscal year ended	Millions of yen	Millions of yen	%	yen
December 31, 2024	1,356	1,035	76.3	4.75
December 31, 2023	1,066	672	62.9	3.86

(Reference) Shareholders' equity: Fiscal year ended December 31, 2024: 1,035 millions of yen
: Fiscal year ended December 31, 2023: 670 millions of yen

The difference between operating results in the fiscal year under review and the preceding fiscal year is attributable to reasons stated in the section titled (1) Overview of operating results for the fiscal year ended December 31, 2024 under 1. Overview of operating results on page 2 of the Attached Material.

* Consolidated financial results reports are not subject to audit procedures by the Company's independent auditor.

* Proper use of earnings forecasts, and other special matters

For the Group's consolidated earnings forecasts contained in these materials, disclosure is made with a range because it is difficult to estimate specific figures.

The forecasts are based on judgments and assumptions derived from information available to the Company as of the date of disclosure of these materials, and actual results may differ from such forecasts due to various factors. For the suppositions that form the assumptions for earnings forecasts and cautions concerning the use thereof, please refer to the section of "(3) Future outlook" on page 5 of the attached material.

The Company plans to hold a financial results presentation meeting for institutional investors and analysts on Monday, February 17, 2025.

The materials used at this meeting shall be posted on the Company's website promptly after the meeting is held.

[Attached Material]

Index

1. Overview of operating results

(1) Overview of operating results for the fiscal year ended December 31, 2024

1) Overview of results

Operating results

(Millions of yen)

	Fiscal year ended December 31, 2023	Fiscal year ended December 31, 2024	Year-on-year
Revenue	617	316	(300)
Gross profit	337	185	(151)
Operating profit (loss)	(1,139)	(1,951)	(811)
Profit (loss)	(1,112)	(1,941)	(828)

The Group intends to focus business operations on expanding its oncology development pipeline, which consists of three products that have already been launched. Under this goal, the Group primarily engaged in the following business activities in the fiscal year ended December 31, 2024.

［Launched products (development completed)］

SP-01 (Indication: **Chemotherapy-induced nausea and vomiting)**

SP-03 (Indication: **Oral mucositis/stomatitis caused by chemotherapy and radiotherapy)**

Sales of Sancuso® (SP-01) and episil® (SP-03), which are mainly sold in China, were substantially lower than in the corresponding period of the previous fiscal year, due to the restricted shipment of Sancuso®(SP-01) and episil®(SP-03) resulting from the addition and relocation of the manufacturing facility in a bid to lower costs. The regulatory procedures for the addition of the Sancuso® manufacturing facility in China have been completed. The Company obtained regulatory approval for the transfer of manufacturing site in Japan for episil® in August 2024, and as of today, the Company obtained regulatory approval in China and Korea. In order to increase the sales volume of episil® (SP-03),The Group resolved to cancel the sales partner agreement with Lee's Pharmaceutical (HK) Limited and enter into a new sales partner agreement with Changchun GeneScience Pharmaceutical Co., Ltd. (headquarters: China; hereinafter "GenSci". The contracting party is Gensci Singapore Pte. Ltd., a wholly owned subsidiary of GenSci.) in December 2024.

SP-02 (Indication: **Relapsed or Refractory Peripheral T-cell Lymphoma)**

The Company obtained marketing approval and began sales for SP-02 in Japan in 2022.

Currently, the Company is investigating new targeting cancers other than Relapsed or Refractory peripheral T-cell lymphoma with an eye to expanding the new indications.

The Company is continuing out-licensing activities for marketing and other rights in China and other regions.

［Pipeline products in the non-clinical study phase］

SP-04 (Target Indication: **Chemotherapy-induced peripheral neuropathy)**

Based on the results of the international Phase III clinical trials (POLAR-A study and POLAR-M study) including Japan in patients with colorectal cancer of SP-04 targeting oxaliplatin-induced peripheral neuropathy, the Company has decided to park the development of the pipeline product for this indication; instead, we have determined to conduct additional animal studies to investigate the product's potential in treating taxane-induced peripheral neuropathy. Based on the information obtained from the results of previous animal studies, in collaboration with licensor Egetis Therapeutics, we have conducted animal study in Japan and have obtained positive results in terms of peripheral neuropathic pain and pathological

evaluation of neuronal cells in the test animals. With a view to future clinical trials, we have also started an additional new animal study to reinforce these results.

Pipeline product (development stopped temporarily)]

SP-05 (Target Indication: **Increase in antitumor efficacy of fluorouracil**)

In 2022, it was found out that neither the primary endpoint nor the key secondary endpoint showed statistically significant differences as the final results of the international Phase III AGENT Study including Japan in colorectal cancer. We have decided to stop to the development of this pipeline product.

The developed product's licensor, Isofol, has been conducting a detailed analysis of the AGENT study results with external professionals and new non-clinical studies since 2023 with a view to resuming clinical development of SP-05, and has concluded that these overall evaluations show that SP-05 (arfolitixorin) is different from that used in the AGENT study in the study concluded that these overall evaluations indicate that SP-05 (arfolitixorin) is clinically effective at new doses and dosages different from those used in the AGENT study.

In February 2024, Isofol's Board of Directors decided to prepare a new clinical development program for SP-05 and to initiate a new clinical trial as soon as possible. In conjunction with this decision, Isofol also announced that it plans to conduct small clinical trials in a time- and cost-efficient manner to demonstrate the clinical efficacy of SP-05 using the new dosage and administration compared to standard therapy as the first approach.

The Company has been in regular communication with Isofol since the suspension of the development of SP-05. In light of Isofol's recent decision to resume development of SP-05 and its plans to conduct a small clinical trial, we will continue to exchange information with Isofol and evaluate the results of the new non-clinical study and the content of the clinical trial plan in order to decide on the resumption of development in Japan and Isofol's plan to participate in a new development program.

In July 2024, Isofol has announced results from a post hoc per-Protocol analysis of the AGENT Study and two preclinical studies that support the dose-response relationship for SP-05(arfolitixorin). The results show even the likely suboptimal dosing regimen used in the Phase III AGENT study results in a numerical advantage for SP-05(arfolitixorin). Additionally, previous studies suggest that an optimized dosing regimen could generate even better efficacy. These preclinical studies confirm previous findings and thereby provide further support for Isofol's strategy to conduct a clinical study with an expected new optimized dosing regimen of arfolitixorin, where higher doses than the one used in the Phase III AGENT study are tested.

At the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) held in the United States in January this year, the details of the post ad-hoc analysis results of the AGENT study were reported, and it was reported that when only the patient group that strictly followed the study protocol was analyzed, the SP-05 administration group showed higher efficacy than the control group that received leucovorin. This is thought to further increase the possibility of obtaining positive data in the Phase Ib/II clinical trial scheduled to begin in the first half of this year.

The Company has made progress in the development of its pipeline products as outlined above and intends to enhance corporate value in the medium to long term through structural reforms implemented the year before last aimed at improving earnings began to produce results. However, in the short term, upfront expenditures for pipeline product development continue to exceed earnings from product sales due to the impact of competing products and the impact of the anti-corruption campaign in China, product sales are struggling to grow. As a result, our financial performance during the fiscal year ended December 31, 2024, was as follows.

[Revenue, gross profit]

In the fiscal year ended December 31, 2024, revenue totaled 316 million yen. Currently, procedures are underway to change the manufacturing site of the drug in a bid to lower manufacturing costs, and we expect prescription volume of the drug to fall temporarily until the procedures are complete. Revenue

mainly came from the sales of pipeline products of DARVIAS® (SP-02) as well as upfront payments for out-licensing of episil® (SP-03) due to a change of sales partner in China. In addition, gross profit amounted to 185 million yen.

Breakdown of R&D and SG&A expenses

(Millions of yen)

	Fiscal year ended December 31, 2023	Fiscal year ended December 31, 2024	Year-on-year
R&D expenses	403	414	11
SG&A expenses	1,073	1,721	648
Total	1,476	2,136	660
(Breakdown) Personnel expenses	470	422	(48)
Outsourcing expenses / Subcontract expenses	410	428	17
Depreciation and amortization of intangible assets	500	1,154	653
Other	94	131	36

[R&D expenses, SG&A expenses, Operating profit (loss), Profit (loss)]

R&D expenses amounted to 414 million yen. This amount mainly reflected costs for changing the manufacturing site to lower manufacturing costs, R&D aimed at preparing the clinical studies and expanding the indications for DARVIAS® (SP-02), animal studies for SP-04, and investments in new development candidates. SG&A expenses amounted to 1,721 million yen, up 648 million yen year on year, as an intangible asset impairment loss of 959 million yen reflecting the delay in the out-licensing of DARVIAS® (SP-02) in China.

The Company incurred an operating loss of 1,951 million yen.

The Company incurred an overall loss of 1,941 million yen.

[Capitalized costs included in intangible assets]

The Group posted no increase in intangible assets attributable to development costs and in-licensing expenses recognized as assets among pipeline investment outlays. In the fiscal year ended December 31, 2024, pipeline investment amounted to 414 million yen. This figure is 414 million yen in R&D expenses. However, amortization of intangible assets related to the pipeline product Sancuso® (SP-01) and ,DARVIAS® (SP-02), leading to amortization of 158 million yen. Further, the Group reported impairment losses for intangible assets amounting to 959 million yen related to the pipeline product. As a result, the balance of intangible assets has become zero as of December 31, 2024.

2) Cash flows

(Millions of yen)

	Fiscal year ended December 31, 2023	Fiscal year ended December 31, 2024	Year-on-year
Net cash provided by (used in) operating activities	(359)	(1,033)	(674)
Net cash provided by (used in) investing activities	(0)	(0)	(0)
Net cash provided by （used in） financing activities	275	1,180	904

[Cash flows from operating activities]

Net cash used in operating activities amounted to 1,033 million yen (compared with 359 million yen in net cash used in these activities in the corresponding period of the previous fiscal year), which was mainly attributable to loss before tax of 1,961 million yen.

[Cash flows from investing activities]

Net cash used in investing activities amounted to 0 million yen (compared with 0 million yen used in these activities in the corresponding period of the previous fiscal year).

[Cash flows from financing activities]

Net cash provided by financing activities amounted to 1,180 million yen (compared with 275 million yen provided by these activities in the same period of the previous year). This figure was mainly attributable to 1,215 million yen in proceeds from issuance of new shares by the exercise of warrants.

3) Research and development activities

R&D expenses amounted to 414 million yen. This amount mainly reflected costs for changing the manufacturing site to lower manufacturing costs, R&D aimed at preparing the clinical studies and expanding the indications for DARVIAS® (SP-02), animal studies for SP-04, and investments in new development candidates..
Details regarding progress achieved with pipeline products are please refer to today’s news release, entitled “Business Overview of Pipeline Products”.

(2) Overview of financial position for the fiscal year ended December 31, 2024

As of December 31, 2024, total assets amounted to 1,362 million yen, down 867 million yen from the previous year-end. Current assets were 1,266 million yen, including 886 million yen in cash and cash equivalents, 232 million yen in trade and other receivables. Non-current assets came to 96 million yen.
Total liabilities totaled 206 million yen, down 148 million yen from the previous year-end. Current liabilities were 193 million yen, including 121 million yen in trade and other payables. Non-current liabilities amounted to 12 million yen.
Total equity equaled 1,156 million yen, down 719 million yen from the previous year-end. The increase was mainly attributable to 1,215 million yen in proceeds from issuance of new shares. The decrease was mainly attributable to the overall loss of 1,941 million yen.

(3) Future outlook

On the premise of the following business progress, we forecast that for the fiscal year ending December 31, 2025, revenue would 1.3 billion yen, while operating loss, loss before tax and bottom-line loss would a loss of 650 million yen.

1) Key assumptions behind the revenue forecast (1.3 billion yen)
We expect to generate a 1.3 billion yen in revenue, mainly from the sales of Sancuso® (SP-01), DARVIAS® (SP-02), episil® (SP-03) and the upfront payment of out-licensing agreement.
As announced on December 27, 2024, the Company will not announce anticipated contract signing timelines for DARVIAS® (SP-02) in China, and the upfront payment of out-licensing agreement is also not included in the total revenue forecast of 1.3 billion yen.

2) Key assumptions behind the operating expense forecast (1.95 billion yen)
We will incur the cost of sales due to product sales of Sancuso® (SP-01), DARVIAS® (SP-02) and episil® (SP-03).
We will invest in new animal studies for SP-04,clinical studies for SP-05.
We expect to incur operating expenses and development investment into new drug candidates.

Because the overall Group expects to continue making upfront investments as described above, we forecast an operating loss, loss before tax, and bottom-line loss is a loss of 650 million yen.

2. Basic rationale for selecting the accounting standard

The Group adopted International Financial Reporting Standards (IFRS) from the fiscal year ended December 31, 2015, in order to improve international comparability and the convenience of financial information in capital markets.

3. Consolidated financial statements and significant notes thereto

(1) Consolidated statement of financial position

(Millions of yen)

	As of December 31, 2023	As of December 31, 2024
Assets		
Current assets		
Cash and cash equivalents	728	886
Trade and other receivables	67	232
Inventories	122	128
Other current assets	58	19
Total current assets	976	1,266
Non-current assets		
Property, plant and equipment	21	19
Light-of-use asset	60	28
Intangible assets	1,117	―
Investments accounted for using equity method	6	1
Other non-current assets	46	46
Total non-current assets	1,252	96
Total assets	2,229	1,362
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	213	121
Lease liabilities	33	25
Other current liabilities	45	47
Total current liabilities	293	193
Non-current liabilities		
Deferred tax liabilities	22	0
Lease liabilities	27	0
Other non-current liabilities	10	10
Total non-current liabilities	61	12
Total liabilities	354	206
Equity		
Share capital	1,596	2,211
Capital surplus	1,657	2,255
Retained earnings	(1,336)	(3,277)
Treasury stock	(69)	(65)
Other components of equity	26	33
Total equity	1,875	1,156
Total liabilities and equity	2,229	1,362

(2) Consolidated statement of profit or loss

(Millions of yen)

	Fiscal year ended December 31, 2023	Fiscal year ended December 31, 2024
Revenue	617	316
Cost of sales	280	131
Gross profit	337	185
Research and development expenses	403	414
Selling, general and administrative expenses	1,073	1,721
Operating profit (loss)	(1,139)	(1,951)
Finance income	10	0
Finance costs	0	5
Other income	0	―
Other costs	―	0
Share of profit (loss) of investments accounted for using equity method	(5)	(4)
Profit (loss) before tax	(1,135)	(1,961)
Income taxes	(22)	(19)
Profit (loss)	(1,112)	(1,941)
Profit (loss) attributable to:		
Owners of parent	(1,112)	(1,941)
Earnings (loss) per share		
Basic earnings (loss) per share [yen]	(6.62)	(9.77)
Diluted earnings (loss) per share [yen]	(6.62)	(9.77)

(3) Consolidated statement of comprehensive income

(Millions of yen)

	Fiscal year ended December 31, 2023	Fiscal year ended December 31, 2024
Profit (loss)	(1,112)	(1,941)
Other comprehensive income		
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	9	7
Subtotal	9	7
Total other comprehensive income	9	7
Comprehensive income	(1,103)	(1,933)
Comprehensive income attributable to:		
Owners of parent	(1,103)	(1,933)

(4) Consolidated statement of changes in equity

(Millions of yen)

					Other components of equity			
	Share capital	Capital surplus	Retained earnings	Treasury shares	Exchange differences on translation of foreign operations	Share acquisition rights	Total Other components of equity	Total equity
Balance at January 1, 2023	1,436	1,500	(223)	(70)	15	3	19	2,662
Comprehensive income								
Profit (loss)	–	–	(1,112)	–	–	–	–	(1,112)
Other comprehensive income	–	–	–	–	9	–	9	9
Total comprehensive income	–	–	(1,112)	–	9	–	9	(1,103)
Transactions with owners								
Exercise of share acquisition rights	160	159	–	–	–	(1)	(1)	318
Disposal of treasury shares	–	–	–	0	–	–	–	0
Share-based payment transactions	–	(2)	–	–	–	–	–	(2)
Total transactions with owners	160	156	–	0	–	(1)	(1)	315
Balance at December 31, 2023	1,596	1,657	(1,336)	(69)	25	1	26	1,875
Balance at January 1, 2024	1,596	1,657	(1,336)	(69)	25	1	26	1,875
Comprehensive income								
Profit (loss)	–	–	(1,941)	–	–	–	–	(1,941)
Other comprehensive income	–	–	–	–	7	–	7	7
Total comprehensive income	–	–	(1941)	–	7	–	7	(1,933)
Transactions with owners								
Exercise of share acquisition rights	614	600	–	–	–	–	–	1,215
Disposal of share acquisition rights	–	–	–	–	–	(1)	(1)	(1)
Disposal of treasury shares	–	–	–	3	–	–	–	3
Share-based payment transactions	–	(2)	–	–	–	–	–	(2)
Total transactions with owners	614	597	–	3	–	(1)	(1)	1,214
Balance at December 31, 2024	2,211	2,255	(3,277)	(65)	33	―	33	1,156

(5) Consolidated statement of cash flows

(Millions of yen)

	Fiscal year ended December 31, 2023	Fiscal year ended December 31, 2024
Cash flows from operating activities		
Profit (loss) before tax	(1,135)	(1,961)
Depreciation and amortization	500	195
Impairment losses	—	959
Finance income	(10)	(3)
Finance costs	0	1
Share of loss (profit) of investments accounted for using equity method	5	4
Decrease (increase) in trade and other receivables	540	(164)
Decrease (increase) in inventories	(108)	(5)
Increase (decrease) in trade and other payables	(118)	(92)
Other	(7)	37
Subtotal	(332)	(1,030)
Interest received	0	0
Interest paid	(0)	(1)
Income taxes paid	(25)	(1)
Net cash provided by (used in) operating activities	(359)	(1,033)
Cash flows from investing activities		
Purchase of property, plant and equipment	(0)	(1)
Other	—	0
Net cash provided by (used in) investing activities	(0)	(0)
Cash flows from financing activities		
Proceeds from issuance of bonds	—	500
Redemption of bonds	—	(500)
Proceeds from issuance of new shares	318	1,215
Proceeds from issuance of share acquisition rights	—	(1)
Repayment of lease liabilities	(42)	(33)
Net cash provided by (used in) financing activities	275	1,180
Net increase (decrease) in cash and cash equivalents	(83)	146
Cash and cash equivalents at beginning of period	803	728
Effect of exchange rate changes on cash and cash equivalents	7	11
Cash and cash equivalents at end of period	728	886

(6) Notes to consolidated financial statements

(Notes on premise of going concern)

No items to report.

(Change in Accounting Policies)

No items to report.

(Segment information)

Disclosure is omitted as the Group has a single reportable segment.

(Per share information)

The basis for calculating basic earnings (loss) per share is as follows.

	Fiscal year ended December 31, 2023	Fiscal year ended December 31, 2024
Profit (loss) attributable to ordinary equity holders of parent		
Profit (loss) attributable to owners of parent (Millions of yen)	(1,112)	(1,941)
Amount not attributable to ordinary equity holders of parent (Millions of yen)	–	–
Profit (loss) attributable to ordinary equity holders of parent (Millions of yen)	(1,112)	(1,941)
Average number of ordinary shares during the period (shares)	168,131,901	198,704,239

The figure for diluted earnings (loss) per share has been presented at an amount equal to that of basic earnings (loss) per share due to antidilutive effects of the share options with share acquisition rights.

(Significant subsequent events)

No items to report.